Scotia Capital’s Arbutus Biopharma ABUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $66.3K | Hold |
14,740
| – | – | ﹤0.01% | 895 |
|
|
2025
Q4 | $70.9K | Hold |
14,740
| – | – | ﹤0.01% | 874 |
|
|
2025
Q3 | $66.9K | Hold |
14,740
| – | – | ﹤0.01% | 892 |
|
|
2025
Q2 | $45.5K | Hold |
14,740
| – | – | ﹤0.01% | 846 |
|
|
2025
Q1 | $51.4K | Hold |
14,740
| – | – | ﹤0.01% | 821 |
|
|
2024
Q4 | $48.2K | Hold |
14,740
| – | – | ﹤0.01% | 832 |
|
|
2024
Q3 | $56.7K | Sell |
14,740
-4,000
| -21% | -$15.3K | ﹤0.01% | 814 |
|
|
2024
Q2 | $57.9K | Sell |
18,740
-10,300
| -35% | -$30.9K | ﹤0.01% | 806 |
|
|
2024
Q1 | $74.9K | Hold |
29,040
| – | – | ﹤0.01% | 800 |
|
|
2023
Q4 | $72.6K | Hold |
29,040
| – | – | ﹤0.01% | 770 |
|
|
2023
Q3 | $59K | Hold |
29,040
| – | – | ﹤0.01% | 749 |
|
|
2023
Q2 | $66.8K | Sell |
29,040
-150
| -0.5% | -$390 | ﹤0.01% | 758 |
|
|
2023
Q1 | $88.5K | Buy |
+29,190
| New | +$82.3K | ﹤0.01% | 748 |
|
|
2021
Q3 | – | Sell |
-11,690
| Closed | -$35K | – | 854 |
|
|
2021
Q2 | $35K | Hold |
11,690
| – | – | ﹤0.01% | 815 |
|
|
2021
Q1 | $39K | Sell |
11,690
-141
| -1% | -$544 | ﹤0.01% | 786 |
|
|
2020
Q4 | $42K | Buy |
11,831
+10
| +0.1% | +$35 | ﹤0.01% | 739 |
|
|
2020
Q3 | $37K | Buy |
11,821
+131
| +1% | +$398 | ﹤0.01% | 688 |
|
|
2020
Q2 | $21K | Hold |
11,690
| – | – | ﹤0.01% | 616 |
|
|
2020
Q1 | $12K | Buy |
11,690
+40
| +0.3% | +$108 | ﹤0.01% | 627 |
|
|
2019
Q4 | $32K | Sell |
11,650
-8,000
| -41% | -$12.9K | ﹤0.01% | 721 |
|
|
2019
Q3 | $30K | Sell |
19,650
-3,000
| -13% | -$5.17K | ﹤0.01% | 708 |
|
|
2019
Q2 | $47K | Sell |
22,650
-200
| -0.9% | -$512 | ﹤0.01% | 705 |
|
|
2019
Q1 | $82K | Hold |
22,850
| – | – | ﹤0.01% | 671 |
|
|
2018
Q4 | $88K | Hold |
22,850
| – | – | ﹤0.01% | 628 |
|
|
2018
Q3 | $216K | Sell |
22,850
-6,200
| -21% | -$61.6K | ﹤0.01% | 661 |
|
|
2018
Q2 | $145K | Hold |
29,050
| – | – | ﹤0.01% | 638 |
|
|
2018
Q1 | $145K | Hold |
29,050
| – | – | ﹤0.01% | 667 |
|
|
2017
Q4 | $147K | Sell |
29,050
-2,600
| -8% | -$15.2K | ﹤0.01% | 679 |
|
|
2017
Q3 | $196K | Buy |
31,650
+10,150
| +47% | +$43.4K | ﹤0.01% | 654 |
|
|
2017
Q2 | $77K | Buy |
21,500
+4,700
| +28% | +$16.2K | ﹤0.01% | 658 |
|
|
2017
Q1 | $55K | Sell |
16,800
-18,700
| -53% | -$51.9K | ﹤0.01% | 713 |
|
|
2016
Q4 | $87K | Buy |
+35,500
| New | +$103K | ﹤0.01% | 770 |
|
|
2015
Q3 | – | Sell |
-11,150
| Closed | -$130K | – | 777 |
|
|
2015
Q2 | $130K | Buy |
+11,150
| New | +$170K | ﹤0.01% | 713 |
|
Other funds holding ABUS
TSC
WCM
VCM
RCMNY
ACM
Scotia Capital's ABUS Position: Q1 2026 in Review
Scotia Capital held its Arbutus Biopharma (ABUS) position steady in Q1 2026 at 14,740 shares worth $66.3K. The position accounts for ﹤0.01% of the portfolio, ranked #895.
Scotia Capital first reported a position in ABUS in Q2 2015 and has held it in 33 quarters since. The position peaked at $216K in Q3 2018. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.
- Scotia Capital held 14,740 shares of Arbutus Biopharma worth $66.3K as of Q1 2026.
- Scotia Capital left its Arbutus Biopharma share count unchanged in Q1 2026.
- Arbutus Biopharma made up ﹤0.01% of Scotia Capital's portfolio in Q1 2026, its #895 holding.
- Scotia Capital first reported a position in Arbutus Biopharma in Q2 2015 and has held it in 33 quarters since.
- Scotia Capital's Arbutus Biopharma position peaked at $216K in Q3 2018.
- 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.
Based on Scotia Capital's 13F filing for Q1 2026, filed 13 May 2026.